Ropeless elevator system guide rail assembly
US-2017036889-A1 · Feb 9, 2017 · US
RNA for treatment of autoimmune diseases
US11701413B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11701413-B2 |
| Application number | US-201816500005-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 10, 2018 |
| Priority date | Apr 11, 2017 |
| Publication date | Jul 18, 2023 |
| Grant date | Jul 18, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating an autoimmune disease in a subject, comprising administering to the subject a composition comprising a non-immunogenic RNA encoding a peptide or polypeptide comprising an autoantigen or a fragment thereof, or a variant of the autoantigen or fragment, wherein the non-immunogenic RNA comprises 1-methyl-pseudouridine, wherein the non-immunogenic RNA is formulated in a F12 liposome, and wherein the composition does not comprise dsRNA. 2. A method of inducing tolerance to autoreactive T cells in a subject, comprising administering to the subject a composition comprising a non-immunogenic RNA encoding a peptide or polypeptide comprising an autoantigen or a fragment thereof, or a variant of the autoantigen or fragment, wherein the non-immunogenic RNA comprises 1-methyl-pseudouridine, wherein the non-immunogenic RNA is formulated in a F12 liposome, and wherein the composition does not comprise dsRNA. 3. The method of claim 2 , wherein the subject has an autoimmune disease. 4. The method of claim 2 , wherein the non-immunogenic RNA when administered does not result in activation of dendritic cells, activation of T cells and/or secretion of IFN-alpha. 5. The method of claim 2 , wherein the non-immunogenic RNA is mRNA or in vitro transcribed RNA. 6. The method of claim 2 , wherein the autoantigen is a T cell-antigen, CNS-derived, a myelin antigen, or Myelin Oligodendrocyte Glycoprotein (MOG). 7. The method of claim 2 , wherein the peptide or polypeptide comprising an autoantigen or a fragment thereof, or a variant of the autoantigen or fragment comprises amino acids 35 to 55 of Myelin Oligodendrocyte Glycoprotein (MOG). 8. The method of claim 2 , wherein the non-immunogenic RNA is formulated in a delivery vehicle.
Assignees
Inventors
Classifications
Modified T or U · CPC title
Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title
DNA (RNA) vaccination · CPC title
DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title
Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11701413B2 cover?
- The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.
- Who is the assignee on this patent?
- BioNTech SE, Tron—Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gm
- What technology area does this patent fall under?
- Primary CPC classification A61K48/005. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).